Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys |
| |
Authors: | Annamaria Coscarella Roberto Liddi Simona Bach Sabrina Zappitelli Renato Urso Antonio Mele Rita De Santis |
| |
Institution: | (1) Biotechnology Research Department, Menarini Ricerche S.p.A., Via Tito Speri 10-00040 Pomezia, Rome, Italy;(2) Pharmacokinetics and Metabolism Department, Menarini Ricerche S.p.A., Via Tito Speri 10-00040 Pomezia, Rome, Italy |
| |
Abstract: | MEN 11300, MEN 11301, and MEN 11303 are three recombinant human hybrid proteins that, as has recently been described, induce
in vitro erythroid differentiation. This article provides data on their pharmacokinetic and immunogenic behavior after repeated
iv administration to cynomolgus monkeys at 0.8 or 1.6 μg/kg doses. Pharmacokinetic data, obtained after the first administration,
showed that the half-life (t
1/2) and clearance (CL) values are dose dependent, with no significant differences among the three hybrid proteins. After the
tenth administration, MEN 11300 and MEN 11301, both at high and low dose, and MEN 11303 at high dose were undetectable in
plasma, whereas MEN 11303 at the lower dose showed no alteration in its pharmacokinetic profile. Immunologic analyses of plasma
provided an explanation for this different pharmacokinetic behavior. In fact, plasma samples from animals treated repeatedly
with MEN 11300 and MEN 11301 showed specific antibody formation in response to both the high- and the low-dose regimens. These
antibodies exerted in vitro a strong neutralizing activity of the hybrid proteins, with a predominant specificity for the
erythropoietin (EPO) portion. By contrast, MEN 11303 at the lower dose did not induce a detectable antibody response whereas
the antibodies observed on the high-dose regimen did not exert neutralizing activity against the hybrid proteins nor against
granulocyte-macrophage colony-stimulating factor (GM-CSF) or EPO. Hematologic parameters were not affected by the treatments,
thus indicating that the anti-EPO neutralizing antibody response does not cross react with the endogenous monkey cytokine.
The overall immunogenicity data suggest that among the three fusion proteins, MEN 11303 could have a lower immunogenic potential. |
| |
Keywords: | Recombinant human hybrid proteins GM-CSF-EPO primate studies hematopoietic growth factors pharmacokinetics |
本文献已被 SpringerLink 等数据库收录! |
|